Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Nexcella Logo
Nexcella Growth Score
75
CB Rank
69246
Heat Score
61
Nexcella Utilize cell therapies to create safe and effective medicines for oncology and other conditions, improving patient outcomes.
Founded
obfuscation
PrivateGrant Los Angeles, California, United States1-10 nexcella.com
Biotechnology
Health Care
Overview

Nexcella
Total Funding
obfuscation
Growth Score
75
Heat Score
61

Total Funding
obfuscation
obfuscation
Grant raised
obfuscation
Growth Score75
-5 pts
in past quarter
Heat Score 61
-16 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Nexcella

CB Rank
69246
Nexcella Utilize cell therapies to create safe and effective medicines for oncology and other conditions, improving patient outcomes.
Founded
obfuscation
PrivateGrant Los Angeles, California, United States1-10 nexcella.com
Biotechnology
Health Care

Funding Rounds

Grant
OBF
in
obfuscation

Key People

Details

Legal Name Nexcella, Inc.
Operating Status Active
Company Type For Profit
About the Company
Nexcella Utilize cell therapies to create safe and effective medicines for oncology and other conditions, improving patient outcomes.
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

NXC-201
A BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy being developed for relapsed/refractory AL amyloidosis and multiple myeloma, with potential expansion into autoimmune diseases.
NEXICART-1
An ongoing Phase 1b/2a clinical trial evaluating the safety and efficacy of NXC-201 in relapsed/refractory multiple myeloma and AL amyloidosis.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant
obfuscation
Grant - Nexcella Logo
Grant - Nexcella
1
obfuscation
California Institute for Regenerative MedicineGrant

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 1

Employee Profiles

News
Technology
View Tech Report

Monthly Web Visits

467
-2.51%
 in past month

IT Spend

$248.1KThis year, Nexcella is projected to spend $248.1K on IT, according to Aberdeen.

Active Website Tech Count

2Nexcella is actively using 2 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and  SSL by Default.
Sub-Organizations
Frequently Asked Questions

Where is Nexcella's headquarters? Nexcella is located in Los Angeles, California, United States.Who invested in Nexcella? Nexcella is funded by California Institute for Regenerative Medicine.When was the last funding round for Nexcella? Nexcella closed its last funding round on
obfuscation
from a Grant round.Who are Nexcella's competitors? Alternatives and possible competitors to Nexcella may include Novartis, Arcellx, and  Bristol-Myers Squibb.How much funding has Nexcella raised to date? Nexcella has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(411cf44 1)
|